Ferroptotic Neurons

Introduction

Ferroptosis is a regulated form of non-apoptotic cell death characterized by iron-dependent lipid peroxidation accumulation and the collapse of cellular antioxidant defenses.^{1Ferroptosis - past, present and future2019 · Cell Discovery · DOI 10.1038/s41421-019-0151-5Open reference} First described in 2012 by Dixon et al. (2012), ferroptosis has emerged as a critical mechanism in neuronal death across multiple neurodegenerative diseases^{2Ferroptosis: an iron-dependent form of nonapoptotic cell death2012 · Cell · DOI 10.1016/j.cell.2012.10.011Open reference} including Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington’s disease (HD), and Multiple System Atrophy (MSA) (Stockwell et al., 2017). Unlike apoptosis, ferroptosis is morphologically and biochemically distinct, featuring shrunken mitochondria with normal-sized nuclei and requiring iron-catalyzed lipid peroxidation rather than caspase activation.

The discovery of ferroptosis has revolutionized our understanding of regulated cell death in the nervous system and opened therapeutic avenues for neurodegenerative disease intervention. Growing evidence suggests that ferroptotic neuronal death contributes significantly to the progressive loss of specific neuronal populations in these disorders, making it a high-priority therapeutic target.

Molecular Mechanisms of Ferroptosis in Neurons

Iron Metabolism Dysregulation

Neuronal ferroptosis is initiated by abnormal iron accumulation within cells. The brain has particularly high iron requirements for oxidative metabolism, myelogenesis, and neurotransmitter synthesis, making neurons especially vulnerable to iron dysregulation (Masaldan et al., 2019).

Key Iron-Related Changes:

• Increased intracellular iron: Upregulation of transferrin receptor 1 (TFR1) and ferritin leads to iron accumulation in neurons

• Dysregulated ferritin: Altered ferritin expression affects iron storage and release

• Neuromelanin binding: In dopamine neurons, neuromelanin serves as both an iron sink and source depending on cellular conditions

• Fenton chemistry: Fe2+ catalyzes the conversion of hydrogen peroxide to hydroxyl radicals via the Fenton reaction

Iron Import/Export Pathways:

• Transferrin (Tf)-TFR1 mediated import

• DMT1 (divalent metal transporter 1)

• Ferroportin (FPN) mediated export

• Hepcidin regulation of ferroportin

Lipid Peroxidation Cascade

The central event in ferroptosis is iron-dependent lipid peroxidation, particularly of polyunsaturated fatty acids (PUFAs) in cellular membranes (Fedorova et al., 2019).

Key Enzymes and Pathways:

• GPX4 (Glutathione Peroxidase 4): The primary enzyme that reduces lipid peroxides. GPX4 deletion or inhibition triggers ferroptosis

• SLC7A11 (System Xc-): Cystine/glutamate antiporter that provides cysteine for glutathione synthesis. Inhibition causes ferroptosis

• ALOX12/ALOX15: Lipoxygenases that catalyze PUFA peroxidation

• ACSL4 (Acyl-CoA Synthetase Long-Chain Family Member 4): Required for incorporating PUFAs into phospholipids

Lipid Peroxidation Products:

• Phosphatidylethanolamine hydroperoxides (PE-OOH)

• Malondialdehyde (MDA)

• 4-hydroxynonenal (4-HNE)

• Isoprostanes

Regulatory Networks

Multiple signaling pathways converge on ferroptosis regulation:

Promoting Pathways:

• NRF2 deficiency: Reduces antioxidant response elements (AREs) (Wang et al., 2022)

• p53 activation: Suppresses SLC7A11 expression

• HIF1alpha stabilization: Under hypoxic conditions

• Autophagy: Selective autophagy of ferritin (ferritinophagy) increases intracellular iron

Inhibiting Pathways:

• NRF2 activation: Increases antioxidant gene expression

• GPX4 activity

• SLC7A11 function

• Ferroptosis suppressor proteins (FSP1, DHODH)

Ferroptosis in Specific Neurodegenerative Diseases

Alzheimer’s Disease

In Alzheimer’s disease, ferroptosis contributes to neuronal loss through multiple mechanisms (Mahoney-Sánchez et al., 2021):

Pathological Links:

• Amyloid-beta interaction: Aβ directly binds transferrin and alters iron metabolism

• Iron accumulation: Excess iron in brain regions with amyloid plaques

• Lipid peroxidation: Elevated 4-HNE and isoprostanes in AD brains

• GPX4 reduction: Decreased GPX4 in AD temporal cortex

• Tau pathology: Iron promotes tau hyperphosphorylation and aggregation

Evidence:

• Post-mortem AD brains show increased iron in neurons and glia

• Elevated lipid peroxidation markers in cerebrospinal fluid (CSF)

• Animal models demonstrate ferroptosis inhibition reduces neuronal death

• Genetic studies link ferroptosis-related genes to AD risk

Regional Vulnerability:

• Hippocampal CA1 neurons particularly susceptible

• Entorhinal cortex shows early iron accumulation

• Frontal cortex affected in later stages

Therapeutic Implications:

• Iron chelation with deferoxamine shows cognitive benefits in clinical trials

• Liproxstatin-1 reduces neuronal loss in AD mouse models

• Vitamin E supplementation has shown cognitive benefit in some AD trials

Clinical Trials:

• Deferoxamine trials (1990s-2000s) showed modest cognitive benefit

• Current trials testing newer chelators ( NCT05745621, NCT05892321)

• Combination approaches under investigation

Parkinson’s Disease

Parkinson’s disease shows particularly strong evidence for ferroptotic mechanisms (Do Van et al., 2016):

Pathological Links:

• Neuromelanin iron binding: The substantia nigra pars compacta (SNc) contains high iron

• Neuromelanin degradation: Releases iron during neurodegeneration

• Lipid peroxidation: Increased 4-HNE in SNc of PD patients

• GPX4 alterations: Changed GPX4 expression in PD brains

• System Xc- dysfunction: Altered cystine uptake in PD models

Evidence:

• Elevated iron in SNc demonstrated by MRI

• Increased lipid peroxidation markers in PD CSF

• Genetic links to iron metabolism genes (PARK8/LRRK2, PARK7/DJ-1)

• Ferroptosis inhibitors protect dopaminergic neurons in vitro

• Post-mortem studies show GPX4 reduction in SNc

Regional Vulnerability:

• Dopaminergic neurons in SNc most affected

• Locus coeruleus also shows iron accumulation

• Dorsal motor nucleus of vagus affected

Therapeutic Approaches:

• Deferoxamine clinical trials for PD (mixed results)

• Iron chelation strategies with newer agents

• NRF2 activators in trials

• GPX4-enhancing compounds in development

Clinical Trials:

• Deferasirox trial (NCT01737030) - completed

• Novel chelator trials ongoing ( NCT06018291)

Amyotrophic Lateral Sclerosis

Ferroptosis is increasingly recognized in ALS (Gladstone et al., 2021):

Evidence:

• ALS mouse models show lipid peroxidation accumulation

• GPX4 reduction in motor neurons

• Iron accumulation in spinal cord

• CSF biomarkers of ferroptosis

SOD1 Models:

• Lipid peroxidation markers elevated

• GPX4 activity reduced

• System Xc- dysfunction present

• Ferrostatin-1 extends survival

C9orf72 Models:

• Repeat expansion affects iron metabolism

• Ferroptosis-related gene expression altered

• Dipeptide repeat proteins affect system Xc-

Therapeutic Targets:

• Ferric citrate reduces progression in mouse models (Devos et al., 2022)

• Liproxstatin-1 extends survival in SOD1 mice

• Ferroptosis-related genes (GPX4, SLC7A11) as therapeutic targets

Clinical Trials:

• Edaravone approved (has antioxidant properties)

• Ferric citrate trial planned

• Combination trials in design

Huntington’s Disease

Huntington’s disease demonstrates ferroptotic features (Borghi et al., 2022):

Evidence:

• Mutant huntingtin affects iron metabolism

• Altered GPX4 and system Xc-

• Lipid peroxidation in HD brain

• Energy metabolism impairment promoting ferroptosis

• Elevated iron in striatum

Mechanisms:

• Mutant huntingtin increases TF1 expression

• Impairs mitochondrial function

• Reduces system Xc- activity

• Alters NRF2 localization

Therapeutic Targets:

• Iron chelation strategies

• Lipid peroxidation inhibitors

• NRF2 activators

• Energy metabolism modulators

Multiple System Atrophy

MSA shows ferroptosis involvement (Chen et al., 2021):

Evidence:

• Oligodendrocyte degeneration involves ferroptosis

• Iron accumulation in striatum

• Oligodendrocyte-specific vulnerability

• Myelin breakdown products promote ferroptosis

Subtypes:

• MSA-C (cerebellar): Cerebellar neurons affected

• MSA-P (parkinsonian): Striatal neurons affected

• Both show iron dysregulation

Therapeutic Approaches:

• Iron chelation

• Lipid peroxidation inhibition

• Oligodendrocyte protection

Stroke and Traumatic Brain Injury

Additional neurological conditions where ferroptosis plays a role (Gao et al., 2019; Anthonym et al., 2020):

Ischemic Stroke:

• Reperfusion injury involves ferroptosis

• Iron released from hemoglobin

• GPX4 inhibition contributes

• Ferroptosis inhibitors reduce infarct size

Hemorrhagic Stroke:

• Iron from blood cells accumulates

• Perihematomal region shows ferroptosis

• Chelation beneficial in models

Traumatic Brain Injury:

• Secondary injury involves ferroptosis

• Iron accumulation post-injury

• Ferroptosis contributes to chronic deficits

Mechanistic Pathways - Detailed Analysis

System Xc- (SLC7A11/SLC3A2) Complex

The cystine/glutamate antiporter system Xc- is critical for ferroptosis regulation (Liu et al., 2020):

Structure:

• Heterodimer of SLC7A11 (xCT) and SLC3A2 (4F2hc)

• 12 transmembrane domains

• Oxidized form transports cystine

Function:

• Imports cystine in exchange for glutamate export

• 1 cystine : 1 glutamate

• Rate depends on cystine gradient

Neurodegeneration Links:

• SLC7A11 expression reduced in PD

• Genetic variants linked to ALS risk

• System Xc- dysfunction promotes ferroptosis

Therapeutic Targeting:

• Inhibitors: Erastin, sulfasalazine

• Activators: N-acetylcysteine, ebselen

GPX4 Pathway

Glutathione peroxidase 4 is the central ferroptosis regulator:

Catalytic Mechanism:

• Uses GSH to reduce lipid peroxides

• Produces GSSG as product

• Selenocysteine active site

Isoforms:

• Cytosolic GPX4 (main form)

• Phospholipid hydroperoxide GPX4 (PHGPX)

• Mitochondrial GPX4

Regulation:

• Transcription via NRF2

• Post-translational modifications

• Selenoprotein expression

In Neurodegeneration:

• GPX4 reduced in AD, PD, ALS

• Post-translational modifications affect activity

• Genetic variants may increase risk

Iron Metabolism in Neurons

Neuronal iron handling is highly regulated (Masaldan et al., 2019; Ayton et al., 2023):

Import:

• Transferrin receptor 1 (TFR1) main pathway

• Non-transferrin bound iron (NTBI) via DMT1

• Ferritin can chaperone iron

Storage:

• Ferritin (FTH1/FTL) stores iron

• Heavy and light subunits

• Can store 4500 iron atoms

Export:

• Ferroportin (FPN) main exporter

• Requires hepcidin regulation

• Ceruloplasmin aids oxidation

Special Considerations:

• High metabolic demand for iron

• Myelin production requires iron

• Neurotransmitter synthesis needs iron

Ferroptosis Signaling Pathways

NRF2 Pathway:

• Master regulator of antioxidant response

• Controls GPX4, SLC7A11, FTH1

• Keap1-NRF2 axis regulation

• NRF2 activators prevent ferroptosis

p53 Pathway:

• p53 suppresses SLC7A11 transcription

• p53 activation promotes ferroptosis

• p53-independent roles also exist

AMPK Pathway:

• Energy stress affects ferroptosis

• AMPK phosphorylation affects synthesis

• Autophagy modulates susceptibility

Mermaid Pathway Diagrams

flowchart TD
    A["Normal Neuron"] --> B["Iron Accumulation"]
    B --> C["Transferrin Receptor Upregulation"]
    B --> D["Ferritin Dysregulation"]
    C --> E["Intracellular Iron Increase"]
    D --> E
    E --> F["Fenton Reaction"]
    F --> G["Lipid Peroxidation"]
    G --> H["GPX4 Inhibition"]
    H --> I["GPX4 Activity Decrease"]
    I --> J["System Xc- Dysfunction"]
    J --> K["Cystine Import Reduced"]
    K --> L["Glutathione Depletion"]
    L --> M["Lipid ROS Accumulation"]
    G --> M
    M --> N["Membrane Damage"]
    N --> O["Ferroptotic Death"]
    style N fill:#3b1114,stroke:#333
    style O fill:#f66,stroke:#333

flowchart LR
    A["Amyloid-beta"] --> B["Iron Metabolism Alteration"]
    C["Alpha-synuclein"] --> B
    D["Mutant Huntingtin"] --> B
    E["TDP-43"] --> B
    B --> F["Neuronal Iron Accumulation"]
    F --> G["Lipid Peroxidation"]
    G --> H["GPX4/System Xc- Dysfunction"]
    H --> I["Ferroptosis"]
    I --> J["Neuronal Death in AD/PD/ALS/HD"]
    style I fill:#3b1114,stroke:#333

Comparison of Cell Death Pathways

Clinical Biomarkers and Diagnosis

Cerebrospinal Fluid Markers

CSF biomarkers provide window into ongoing neuronal injury (Connelly et al., 2019):

Established Markers:

• Lipid peroxidation products: 4-HNE, MDA, isoprostanes

  • 4-HNE-protein adducts elevated in AD, PD

  • Isoprostanes reflect oxidative stress

  • Correlate with disease severity

• Iron indices: Ferritin, transferrin

  • Elevated ferritin in some conditions

  • Transferrin saturation changes

• GPX4 activity: Challenging to measure directly

Emerging Markers:

• Phospholipid hydroperoxides detection

• Free iron imaging probes (FeRhoNox)

• System Xc- functional assays

Imaging Biomarkers

Quantitative Susceptibility Mapping (QSM) MRI:

• Direct iron quantification in brain

• Regional sensitivity across brain regions

• Correlates with clinical measures in PD and AD

R2 Relaxometry:*

• Iron-sensitive MRI technique

• Substantia nigra iron measurement in PD

• Correlation with disease duration and severity

PET Tracers:

• Ferroptosis-specific tracers in development

• Not yet validated for clinical use in neurodegeneration

Clinical Utility

Current biomarker applications:

• Trial enrichment: Patient selection based on biomarkers

• Target engagement: Measure drug effects

• Disease progression: Track changes over time

• Prognostic utility: Risk stratification in early disease

Therapeutic Agents in Detail

Iron Chelators

Deferoxamine (DFO):

• Classic iron chelator with established mechanisms

• Poor BBB penetration limits efficacy

• Subcutaneous administration required

• Used historically in PD trials (mixed results)

• Limited brain efficacy at therapeutic doses

Deferasirox (Jadenu):

• Oral chelator with better compliance

• Improved tolerance profile

• Modest brain penetration achieved

• Clinical trials in PD and ALS ongoing

• Acceptable safety profile established

Clioquinol:

• 8-hydroxyquinoline compound

• Multiple metal binding capacity (Cu, Zn, Fe)

• Promotes metalloprotein function

• Phase trials conducted in AD with mixed outcomes

PBT434:

• Novel quinoline derivative

• Enhanced brain-penetrant properties

• Strong preclinical promise

• Entering clinical trials soon

Antioxidants

Vitamin E:

• Chain-terminating antioxidant mechanism

• Clinical trials in AD showed benefit in some studies

• May slow disease progression modestly

• Safe at high doses with monitoring

Edaravone:

• FDA-approved for ALS treatment

• Multiple antioxidant properties

• NRF2 activation contributes to efficacy

• Demonstrated modest efficacy in ALS trials

Ferrostatin-1:

• Potent ferroptosis inhibitor

• Radical trapping mechanism

• Excellent efficacy in disease models

• Poor drug-like properties limit clinical use

Liproxstatin-1:

• Lipoxygenase inhibition activity

• Improved brain-penetrant properties

• Strong preclinical efficacy

• Significant clinical development potential

NRF2 Activators

Sulforaphane:

• Broccoli-derived compound

• Potent NRF2 activation

• Multiple antioxidant targets

• Active clinical investigation for neurodegeneration

Dimethyl fumarate:

• Approved treatment for MS

• Demonstrated NRF2 effects

• Potential to reduce ferroptosis

• Well-established safety profile

System Xc- Modulators

N-acetylcysteine (NAC):

• Glutathione precursor pathway

• Alternative cystine source

• Used in psychiatric conditions

• Limited efficacy in neurodegeneration trials

Ebselen:

• GPX4 mimetic compound

• Multi-faceted antioxidant effects

• Active clinical trials in PD

• Favorable safety profile established

Genetic Risk Factors

GWAS Findings

Genome-wide association studies increasingly implicate ferroptosis-related genes in neurodegenerative disease risk:

Alzheimer’s Disease:

• ABCA7 influences lipid transport

• CLU (clusterin) modifies risk

• PICALM affects clathrin function

Parkinson’s Disease:

• PARK7 (DJ-1) impacts antioxidant function

• PARK8 (LRRK2) shows iron metabolism links

• GBA affects lipid handling

ALS:

• C9orf72 repeat expansion mechanism

• SOD1 modifies antioxidant function

• OPTN influences autophagy

Gene Expression Studies

RNA-seq analysis in neurodegeneration reveals:

• GPX4 expression reduced across disease conditions

• SLC7A11 downregulated specifically in PD

• Iron metabolism genes show altered expression

• ALOX15 upregulated in affected tissues

Therapeutic Development Pipeline

Preclinical Candidates

Clinical Candidates

Morphological and Biochemical Hallmarks

Cellular Morphology

Ferroptotic neurons exhibit distinctive features:

• Mitochondria: Small, electron-dense, wrinkled membrane

• Nucleus: Normal size with intact membrane (unlike apoptosis)

• Cytoplasm: Electron-dense with lipid droplets

• Membrane: Intact plasma membrane (unlike necrosis)

• No apoptotic bodies: Distinct from apoptosis

Biochemical Markers

In Situ Markers:

• GPX4 loss

• ACSL4 upregulation

• Lipid ROS accumulation (BODIPY-C11)

• Free iron increase (FeRhoNox)

Soluble Biomarkers:

• Increased lipid peroxidation products in CSF (Connelly et al., 2019)

• Decreased GPX4 activity

• Altered iron indices

Therapeutic Strategies

Iron Chelation

Clinical Approaches:

• Deferoxamine (DFO): Iron chelator, shown benefit in PD and AD trials

• Deferasirox (Jadenu): Oral iron chelator

• Clioquinol: 8-hydroxyquinoline with iron chelation properties

• PBT434: Novel brain-penetrant iron chelator

Considerations:

• Blood-brain barrier penetration critical

• Need to balance iron chelation with essential functions

• Timing of intervention matters

Lipid Peroxidation Inhibitors

Direct Inhibitors:

• Ferrostatin-1: Potent peroxyl radical scavenger

• Liproxstatin-1: Inhibits lipid ROS generation

• Vitamin E: Chain-terminating antioxidant

• Edaravone: Approved for ALS, has antioxidant properties

Mechanistic Inhibitors:

• Selenium: Cofactor for GPX4 activity

• Statins: Pleiotropic antioxidant effects

System Xc- Modulation

Approaches:

• Sulfasalazine: System Xc- inhibitor (use with caution)

• Ebselen: GPX4 mimic

• N-acetylcysteine: Glutathione precursor

NRF2 Activation

Natural and pharmacological NRF2 activators:

• Sulforaphane: Broccoli-derived NRF2 activator

• Dimethyl fumarate: Approved for MS, activates NRF2

• Oltipraz: NRF2 activator

• CDDO derivatives: Synthetic triterpenoids

Autophagy Modulation

• Chloroquine: Autophagy inhibitor (dual effect)

• Bafilomycin: V-ATPase inhibitor

• 3-Methyladenine: PI3K inhibitor

Animal Models and Research tools

Genetic Models

• GPX4 conditional knockout: Induces neuronal ferroptosis

• SLC7A11 knockout: System Xc- deficiency models

• Fth1 (ferritin heavy) knockout: Iron accumulation

• NRF2 knockout: Antioxidant deficiency

Chemical Inducers

• Erastin: System Xc- inhibitor

• RSL3: GPX4 inhibitor

• FIN56: GPX4 degradation activator

• Glutamate: Excitotoxicity via system Xc-

Chemical Inhibitors

• Ferrostatin-1: Radical trapping antioxidant

• Liproxstatin-1: Lipoxygenase inhibitor

• Deferoxamine: Iron chelator

• Vitamin E: Antioxidant

Diagnostic and Prognostic Biomarkers

Cerebrospinal Fluid Biomarkers

Based on current research, potential biomarkers include:

• Lipid peroxidation products: 4-HNE, MDA, isoprostanes

• Iron indices: Ferritin, transferrin

• GPX4 activity: Direct measurement challenging

Imaging Biomarkers

• Quantitative susceptibility mapping (QSM) MRI: Brain iron quantification

• R2 mapping*: Iron-sensitive MRI

• PET markers: Under development

Clinical Considerations

• Peripheral biomarkers less reliable: Blood-brain barrier limits translation

• Combination approaches needed: Multiple markers increase specificity

• Timing important: Biomarkers change with disease stage

Research Directions and Future Perspectives

Open Questions

1. What determines neuronal susceptibility to ferroptosis?

2. How does ferroptosis interact with other cell death pathways?

3. Can ferroptosis be selectively triggered in diseased neurons?

4. What is the temporal relationship between ferroptosis and protein aggregation?

5. How do genetic risk factors modulate ferroptosis?

Emerging Therapeutic Approaches

• Gene therapy: Deliver GPX4 or system Xc-

• Small molecule development: Brain-penetrant ferroptosis inhibitors

• Combination therapies: Chelation plus antioxidant

• Biomarker development: Patient selection for trials

Clinical Trial Considerations

• Patient selection: Based on biomarker evidence

• Timing: Early intervention likely more effective

• Combination approaches: Target multiple pathways

• Biomarker-driven: Use biomarkers for response

Summary

Ferroptosis represents a significant mechanism of neuronal death in neurodegenerative diseases. The iron-dependent lipid peroxidation that defines ferroptosis provides therapeutic targets not addressed by traditional approaches. Key points include:

1. Evidence: Strong evidence for ferroptosis in AD, PD, ALS, HD, and MSA

2. Mechanisms: Iron accumulation, lipid peroxidation, GPX4/system Xc- dysfunction

3. Therapeutic targets: Iron chelation, lipid peroxidation inhibitors, NRF2 activators

4. Challenges: Biomarker development, patient selection, timing of intervention

5. Future: Growing therapeutic pipeline and clinical trial potential

As research progresses, ferroptosis-based therapies may provide meaningful disease modification for neurodegenerative diseases currently lacking effective treatments.

Future Directions

Unmet Needs

1. Validated biomarkers for patient selection and disease monitoring

2. Brain-penetrant ferroptosis inhibitors with good drug-like properties

3. Understanding of ferroptosis crosstalk with other cell death pathways

4. Temporal mapping of ferroptosis in disease progression

5. Combination approaches targeting multiple mechanisms

Research Priorities

• Develop sensitive CSF and blood biomarkers for ferroptosis

• Create brain-penetrant small molecule inhibitors

• Identify optimal intervention windows in disease

• Understand interactions with protein aggregation

• Define genetic susceptibility factors

Integration with NeuroWiki

This mechanism connects to multiple NeuroWiki pages:

• Iron Metabolism - Central to ferroptosis

• GPX4 - Key regulatory enzyme

• System Xc- - Cystine transporter

• Alzheimer’s Disease - Ferroptosis in AD

• Parkinson’s Disease - Ferroptosis in PD

• Amyotrophic Lateral Sclerosis - Ferroptosis in ALS

• Lipid Peroxidation - Core mechanism

Additional Disease Connections

Beyond the major neurodegenerative diseases, ferroptosis contributes to:

Amyotrophic Lateral Sclerosis:

• Motor neuron vulnerability is pronounced

• Lipid peroxidation accumulates in spinal cord

• System Xc- shows reduced activity

• GPX4 expression diminished in models

Multiple System Atrophy:

• Oligodendrocyte sensitivity notable

• Iron accumulates in striatum

• Myelin breakdown enhances vulnerability

Stroke:

• Ischemia-reperfusion triggers ferroptosis

• Ferrostatin-1 reduces infarct size

• Adjunctive therapy potential exists

Traumatic Brain Injury:

• Secondary injury involves ferroptosis mechanisms

• Iron released post-injury worsens outcomes

• Early intervention shows promise

Brain Aging:

• Iron accumulates with normal aging

• GPX4 activity declines

• Ferroptosis vulnerability increases

Model Systems

Cell culture and animal models enable mechanistic investigation:

Cell Lines Used:

• SH-SY5Y human neuroblastoma

• PC12 rat pheochromocytoma

• Primary cortical neurons

• iPSC-derived dopaminergic neurons

Animal Models:

• Transgenic overexpressing mice

• Knockout mouse models

• Chemically induced parkinsonism

• ALS genetic models

This comprehensive mechanistic understanding positions ferroptosis as a high-value therapeutic target in NeuroWiki’s mission to map neurodegenerative disease mechanisms.

See Also

Related Hypotheses:

• ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia

• Senescence-Induced Lipid Peroxidation Spreading

• Magnetosonic-Triggered Transferrin Receptor Clustering

• Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioenergetics

• Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancement

Related Analyses:

• Senolytic therapy for age-related neurodegeneration

• Selective vulnerability of entorhinal cortex layer II neurons in AD

• Blood-brain barrier transport mechanisms for antibody therapeutics

Related Experiments:

• ER-Golgi Secretory Pathway Dysfunction in PD - Experiment Design

• Ferroptosis Validation in Parkinson’s Disease

• Peroxisome Dysfunction Validation in Parkinson’s Disease

Pathway Diagram

The following diagram shows the key molecular relationships involving Ferroptotic Neurons discovered through SciDEX knowledge graph analysis:

graph TD
    Tat_NTS_peptide["Tat-NTS peptide"] -->|"protects against"| NEURONS["NEURONS"]
    GLIA["GLIA"] -->|"interacts with"| NEURONS["NEURONS"]
    TNF__["TNF-α"] -->|"induces"| NEURONS["NEURONS"]
    MICROGLIA["MICROGLIA"] -->|"kills"| NEURONS["NEURONS"]
    PRION_DISEASES["PRION DISEASES"] -->|"causes injury to"| NEURONS["NEURONS"]
    CHRONIC_TRAUMATIC_ENCEPHALOPAT["CHRONIC TRAUMATIC ENCEPHALOPATHY"] -->|"causes injury to"| NEURONS["NEURONS"]
    AUTOPHAGY["AUTOPHAGY"] -->|"preludes dysfunction"| NEURONS["NEURONS"]
    __Synuclein["α-Synuclein"] -->|"interacts with"| NEURONS["NEURONS"]
    ALZHEIMER_S["ALZHEIMER'S"] -->|"causes injury to"| NEURONS["NEURONS"]
    MICROGLIA["MICROGLIA"] -->|"damages"| NEURONS["NEURONS"]
    PARKINSON_S["PARKINSON'S"] -->|"causes injury to"| NEURONS["NEURONS"]
    HUNTINGTON_S["HUNTINGTON'S"] -->|"causes injury to"| NEURONS["NEURONS"]
    AMYOTROPHIC_LATERAL_SCLEROSIS["AMYOTROPHIC LATERAL SCLEROSIS"] -->|"causes injury to"| NEURONS["NEURONS"]
    FRONTOTEMPORAL_DEMENTIA["FRONTOTEMPORAL DEMENTIA"] -->|"causes injury to"| NEURONS["NEURONS"]
    AUTOPHAGY_FAILURE["AUTOPHAGY FAILURE"] -->|"heightens vulnerabil"| NEURONS["NEURONS"]
    style Tat_NTS_peptide fill:#ff8a65,stroke:#333,color:#000
    style NEURONS fill:#80deea,stroke:#333,color:#000
    style GLIA fill:#80deea,stroke:#333,color:#000
    style TNF__ fill:#4fc3f7,stroke:#333,color:#000
    style MICROGLIA fill:#80deea,stroke:#333,color:#000
    style PRION_DISEASES fill:#ef5350,stroke:#333,color:#000
    style CHRONIC_TRAUMATIC_ENCEPHALOPAT fill:#ef5350,stroke:#333,color:#000
    style AUTOPHAGY fill:#4fc3f7,stroke:#333,color:#000
    style __Synuclein fill:#4fc3f7,stroke:#333,color:#000
    style ALZHEIMER_S fill:#ef5350,stroke:#333,color:#000
    style PARKINSON_S fill:#ef5350,stroke:#333,color:#000
    style HUNTINGTON_S fill:#ef5350,stroke:#333,color:#000
    style AMYOTROPHIC_LATERAL_SCLEROSIS fill:#ef5350,stroke:#333,color:#000
    style FRONTOTEMPORAL_DEMENTIA fill:#ef5350,stroke:#333,color:#000
    style AUTOPHAGY_FAILURE fill:#ffd54f,stroke:#333,color:#000